Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling
- PMID: 1559308
- DOI: 10.2165/00003088-199222010-00006
Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling
Abstract
It was the purpose of this study to evaluate the effect of quinidine administration on the population estimates of the volume of distribution (Vdpop) and clearance (CLpop) of digoxin. The data collected on 94 patients included 230 measured serum digoxin concentrations, height, age, sex, weight (wt), serum creatinine, history of digoxin and quinidine administration and the presence or absence of congestive heart failure (CHF). Using the NONMEM software program, estimates were obtained for CLpop and Vdpop. Variables tested for inclusion in the CLpop model were creatinine clearance (CLCR), CHF, wt, ideal bodyweight, quinidine (QUIN) [both as a discrete variable and in a dose-dependent manner], and body surface area. Variables tested for inclusion in the Vdpop model were CLCR, wt, ideal bodyweight, body surface area and quinidine. During model building a p-value of 0.05 was chosen for variable inclusion. The final model was as follows: CLpop (L/h) = (3.1 + 0.0516 x CLCR) x QUIN Vdpop (L) = (4.03 + 0.0832 x CLCR) x wt F = 0.82 where F is bioavailability. In the above, QUIN is 0.567 if quinidine is being concurrently administered and 1.0 if it is not. The coefficient of variation (CV) of CLpop was 44% while that of Vdpop was 48%. The residual intrasubject CV was 26%. These results compare favourably with previously derived methods of estimating digoxin CLpop and Vdpop but may improve on those methods due to the inclusion of quinidine in the model. These better estimates should result in improved initial dosage of digoxin.
Similar articles
-
Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.Ther Drug Monit. 1996 Feb;18(1):46-52. doi: 10.1097/00007691-199602000-00008. Ther Drug Monit. 1996. PMID: 8848820 Clinical Trial.
-
Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling.Drugs Aging. 2011 Oct 1;28(10):831-41. doi: 10.2165/11594230-000000000-00000. Drugs Aging. 2011. PMID: 21970310
-
Direct comparison of three methods for predicting digoxin concentrations.Pharmacotherapy. 1996 Nov-Dec;16(6):1085-92. Pharmacotherapy. 1996. PMID: 8947982
-
A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.Br J Clin Pharmacol. 2020 Jul;86(7):1267-1280. doi: 10.1111/bcp.14272. Epub 2020 Apr 1. Br J Clin Pharmacol. 2020. PMID: 32153059 Free PMC article.
-
Pharmacokinetic interactions with digoxin.Clin Pharmacokinet. 1988 Oct;15(4):227-44. doi: 10.2165/00003088-198815040-00003. Clin Pharmacokinet. 1988. PMID: 3056649 Review.
Cited by
-
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.Eur J Clin Pharmacol. 2003 Mar;58(11):747-55. doi: 10.1007/s00228-002-0553-3. Epub 2003 Feb 19. Eur J Clin Pharmacol. 2003. PMID: 12634981 Clinical Trial.
-
Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.J Pharmacokinet Biopharm. 1994 Apr;22(2):165-77. doi: 10.1007/BF02353542. J Pharmacokinet Biopharm. 1994. PMID: 7815312
-
Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.Clin Pharmacokinet. 1997 Apr;32(4):294-312. doi: 10.2165/00003088-199732040-00003. Clin Pharmacokinet. 1997. PMID: 9113438 Review.
-
Population pharmacokinetics of ondansetron: a covariate analysis.Br J Clin Pharmacol. 1998 Aug;46(2):117-25. doi: 10.1046/j.1365-2125.1998.00756.x. Br J Clin Pharmacol. 1998. PMID: 9723819 Free PMC article.
-
Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.Clin Pharmacokinet. 2001;40(10):773-81. doi: 10.2165/00003088-200140100-00005. Clin Pharmacokinet. 2001. PMID: 11707062
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical